Arthrosi Forms $59 Million China JV with ApicHope for Gout Therapy
publication date: Aug 19, 2021
Arthrosi Therapeutics of San Diego will form a Guangzhou JV to develop its clinical-stage gout treatment in China. Arthrosi founded the JV with Ruiao Biopharma, a subsidiary of China's ApicHope, which will contribute $34 million for clinical development in China and invest $25 million in Arthrosi's C funding round. Arthrosi said AR882 has produced Phase I/IIa data with high efficacy and safety. Also, the JV will advance AR035, an EGFR exon 20 inhibitor targeting non-small cell lung cancer, into the IND-enabling stage. More details....
Stock Symbol: (SHZ: 300723)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.